

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2999387

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
HUMANETICS CORPORATION	08/18/2014

**RECEIVING PARTY DATA**

<b>Name:</b>	INTERHEALTH NUTRACEUTICALS INCORPORATED
<b>Street Address:</b>	5451 INDUSTRIAL WAY
<b>City:</b>	BENECIA
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94510

**PROPERTY NUMBERS Total: 47**

Property Type	Number
Application Number:	07575156
Patent Number:	5296481
Patent Number:	5292730
Patent Number:	5585371
Patent Number:	5641766
Patent Number:	5707983
Patent Number:	5885977
Patent Number:	5869709
Patent Number:	6111118
Patent Number:	6686486
Patent Number:	6252119
Application Number:	60078978
Patent Number:	6384251
Application Number:	60066198
Patent Number:	6372732
Patent Number:	6593316
Patent Number:	6924274
Application Number:	60066197
Patent Number:	6794374
Patent Number:	6153606
Patent Number:	6489313

PATENT

Property Type	Number
Application Number:	60142709
Application Number:	09611762
Application Number:	09665640
Application Number:	60250227
Patent Number:	7553829
Patent Number:	6399085
Patent Number:	6399084
Patent Number:	6465446
Application Number:	60604626
Application Number:	60604625
Application Number:	60604527
Application Number:	60439753
Application Number:	10541781
Patent Number:	7199116
Application Number:	60439816
Application Number:	10541780
Application Number:	60488433
Application Number:	10892060
Application Number:	60488695
Application Number:	10893445
Application Number:	60488412
Application Number:	10892059
Application Number:	60488429
Application Number:	60604721
Application Number:	60599469
Application Number:	11570903

**CORRESPONDENCE DATA**

**Fax Number:** (302)636-5454

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 202-408-3121 X62348

**Email:** jpaterso@cscinfo.com

**Correspondent Name:** CORPORATION SERVICE COMPANY

**Address Line 1:** 1090 VERMONT AVENUE NW, SUITE 430

**Address Line 4:** WASHINGTON, D.C. 20005

<b>ATTORNEY DOCKET NUMBER:</b>	274076
<b>NAME OF SUBMITTER:</b>	JEAN PATERSON
<b>SIGNATURE:</b>	/jep/
<b>DATE SIGNED:</b>	08/27/2014

**PATENT**

**REEL: 033645 FRAME: 0213**

**Total Attachments: 20**

source=8-27-14 Humanetics-PT#page1.tif  
source=8-27-14 Humanetics-PT#page2.tif  
source=8-27-14 Humanetics-PT#page3.tif  
source=8-27-14 Humanetics-PT#page4.tif  
source=8-27-14 Humanetics-PT#page5.tif  
source=8-27-14 Humanetics-PT#page6.tif  
source=8-27-14 Humanetics-PT#page7.tif  
source=8-27-14 Humanetics-PT#page8.tif  
source=8-27-14 Humanetics-PT#page9.tif  
source=8-27-14 Humanetics-PT#page10.tif  
source=8-27-14 Humanetics-PT#page11.tif  
source=8-27-14 Humanetics-PT#page12.tif  
source=8-27-14 Humanetics-PT#page13.tif  
source=8-27-14 Humanetics-PT#page14.tif  
source=8-27-14 Humanetics-PT#page15.tif  
source=8-27-14 Humanetics-PT#page16.tif  
source=8-27-14 Humanetics-PT#page17.tif  
source=8-27-14 Humanetics-PT#page18.tif  
source=8-27-14 Humanetics-PT#page19.tif  
source=8-27-14 Humanetics-PT#page20.tif

## PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Assignment") is entered into as of August 18, 2014, by and between Humanetics Corporation, a Minnesota corporation ("Assignor") and InterHealth Nutraceuticals Incorporated, a California corporation ("Assignee"). Capitalized terms used but not defined in this Assignment shall have the meanings given to such terms in the Purchase Agreement (as defined below).

### RECITALS

WHEREAS, Assignor and Assignee have entered into that certain Patent and Technology Purchase Agreement, dated as of July 22, 2014 (the "Purchase Agreement"), pursuant to which Assignor has agreed to sell, transfer, convey, assign and deliver to Assignee all right, title and interest in, to and under the Assigned Assets (including, without limitation, the Assigned Patents (as defined below)), and Assignee has agreed to purchase and acquire all right, title and interest in, to and under the Assigned Assets from Assignor, upon the terms and subject to the conditions of the Purchase Agreement; and

WHEREAS, Assignor and Assignee desire to carry out the intent and purpose of the Purchase Agreement by execution and delivery of this Assignment, subject to the provisions of the Purchase Agreement.

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee agree as follows:

1. Assigned Patents. "Assigned Patents" means any and all patents and patent applications which are Assigned Assets, including, without limitation, any continuation, continuation-in-part, divisional and provisional applications and any patents issuing thereon and any reissues, reexaminations, reviews, substitutes and extensions of any of the foregoing, in each case, and including, without limitation, the patents and patent applications set forth on Schedule 1 attached hereto.

2. Assignment. Subject to the terms and conditions of this Assignment and the Purchase Agreement, Assignor hereby sells, transfers, conveys, assigns and delivers to Assignee all of Assignor's right, title, and interest throughout the world in, to and under the Assigned Patents, together with all rights, claims and privileges pertaining to any of the Assigned Patents, including, without limitation, (a) worldwide rights to have the Assigned Patents issued in the name of the Assignee and all other legal rights to which the original owner of the Assigned Patents is or was entitled, (b) the right to prosecute and maintain any of the Assigned Patents, (c) the right to sue and recover damages or injunctive relief for past, present and future infringement, dilution or violation of any of the Assigned Patents, (d) the right to all income, royalties, damages, payments and any other remedies now or hereafter due or payable with respect to any of the Assigned Patents and (e) all corresponding domestic and foreign patents, patent applications, provisional patents, counterparts, certificates of invention, utility models, industrial design protection, design patent protection and other governmental grants or issuances and rights to apply for any of the foregoing in any jurisdiction in the world.

3. Further Assurances. Assignor shall take all actions reasonably requested by Assignee and shall execute any documents as may be reasonably requested by Assignee, from time to time, to fully vest or perfect in Assignee all right, title and interest in, to and under all of the Assigned Patents. Such actions shall include, without limitation, providing documents and information useful or necessary for Assignee or any of its Affiliates, designees or agents to prosecute or maintain any registration or application for any of the Assigned Patents or pursue or defend any administrative, court or other Proceeding involving any of the Assigned Patents. Assignor hereby authorizes the respective patent office or governmental agency in each jurisdiction to issue any and all patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon any of the Assigned Patents in the name of Assignee, as the assignee to the entire interest therein.

4. Conflicts with Purchase Agreement. To the extent there is a conflict between the terms and provisions of this Assignment and the Purchase Agreement, the terms and provisions of the Purchase Agreement will govern.

5. Severability. If any term or other provision of this Assignment is invalid, illegal, or incapable of being enforced by any law or public policy, all other terms or provisions of this Assignment shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Assignment so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.

6. Headings. The section headings contained in this Assignment are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Assignment.

7. Notices. Any notice, request, or other document to be given hereunder to any party hereto shall be given in the manner specified in the Purchase Agreement. Any party hereto may change its address for receiving notices, requests and other documents by giving written notice of such change to the other parties hereto in accordance with the Purchase Agreement.

8. No Third Party Beneficiaries. This Assignment shall not confer any rights or remedies upon any Person other than Assignee and Assignor and their respective successors and permitted assigns.

9. Successors. This Assignment shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns.

10. Governing Law. This Assignment, the rights and obligations of the parties under this Assignment, and any claim or controversy directly or indirectly based upon or arising out of, this Assignment or the transactions contemplated by this Assignment (whether based upon contract, tort or any other theory), including all matters of construction, validity and

performance, shall be governed by and construed in accordance with the laws of the State of California, without regard to any conflict of laws provisions that would require the application of the law of any other jurisdiction.

11. Counterparts. This Assignment may be executed in one or more counterparts (including by facsimile or electronic transmission), each of which will be deemed to be an original copy of this Assignment and all of which, when taken together, will be deemed to constitute one and the same agreement.

12. Entire Agreement. This Assignment and the Purchase Agreement (including the schedules and exhibits hereto and thereto) represent the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersede all prior agreements and undertakings, both written and oral, between Assignor and Assignee with respect to the subject matter hereof and thereof.

13. Amendment. This Assignment may not be amended or modified except (a) by an instrument in writing signed by, or on behalf of, Assignor and Assignee or (b) by a waiver in accordance with Section 14.

14. Waiver. Any waiver of any term or condition of this Assignment shall be valid only if set forth in an instrument in writing signed by Assignor and Assignee. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Assignment. The failure of a party or parties hereto to assert any of their rights hereunder shall not constitute a waiver of any of such rights.

*[The remainder of this page is intentionally left blank.]*

IN WITNESS WHEREOF, the undersigned have caused this Assignment to be duly executed and delivered as of the date first set forth above.

**INTERHEALTH NUTRACEUTICALS  
INCORPORATED**

By: 

Name: Paul S. J. Dijkstra  
Title: Chief Executive Officer

**HUMANETICS CORPORATION**

By: \_\_\_\_\_


Name: Ronald J. Zenk  
Title: President

IN WITNESS WHEREOF, the undersigned have caused this Assignment to be duly executed and delivered as of the date first set forth above.

**INTERHEALTH NUTRACEUTICALS  
INCORPORATED**

By: \_\_\_\_\_  
Name: Paul S. J. Dijkstra  
Title: Chief Executive Officer

**HUMANETICS CORPORATION**

By:   
Name: Ronald J. Zenk  
Title: President

SIGNATURE PAGE TO PATENT ASSIGNMENT

**PATENT  
REEL: 033645 FRAME: 0219**



**Schedule A**

**Patents and Patent Applications**

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
028AUP01 (Australia)	Patent Expired MF	TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED Δ5 -ANDROSTENE	<b>Serial No.</b> 85418/91 <b>Patent No.</b> 647,528
028CAP01 (Canada)	Application Abandoned	TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED Δ5 -ANDROSTENE	<b>Serial No.</b> 2,090,759 <b>Patent No.</b>
028USPT01 (United States)	Application Abandoned	TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED Δ5 -ANDROSTENE	<b>Serial No.</b> 07/575,156 <b>Patent No.</b>
028CAP03 (Canada)	Patent Expired MF	TREATMENT OF ALZHEIMER'S DISEASE AND MODULATION OF IMMUNE SYSTEM WITH Δ5- ANDROSTENES	<b>Serial No.</b> 2,141,436 <b>Patent No.</b> 2,141,436
028EPPT01 (Europe) Validated in AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL and SE,	Patent Expired MF	TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED Δ5-ANDROSTENE	<b>Serial No.</b> 91917276.7 <b>Patent No.</b> 547,151
028WOPT01 (PCT)	Completed	TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED Δ5 -ANDROSTENE	<b>Serial No.</b> PCT/US91/06147 <b>Patent No.</b>
028EPPT03 (Europe)	Patent Expired	TREATMENT OF ALZHEIMERS'S DISEASE	<b>Serial No.</b> 93919879.2

*Schedule A to Assignment of Patents*

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
Validated in DE, FR and GB	MF	WITH $\Delta 5$ -ANDROSTENE	<b>Patent No.</b> <b>746,322</b>
028WOPT03 (PCT)	Completed	MODULATION OF IMMUNE SYSTEM WITH $\Delta 5$ - ANDROSTENES	<b>Serial No.</b> PCT/US93/07327 <b>Patent No.</b>
028EPPT05 (Europe)	Patent Expired MF	TREATMENT OF ALZHEIMER'S DISEASE AND MODULATION OF IMMUNE SYSTEM WITH $\Delta 5$ - ANDROSTENE	<b>Serial No.</b> 99104166.6 <b>Patent No.</b>
028JPPT03 (Japan)	Patent Expired MF	TREATMENT OF ALZHEIMER'S DISEASE WITH $\Delta 5$ - ANDROSTENES	<b>Serial No.</b> Hei 6-505536 <b>Patent No.</b> 2,762,315
028USPT02 (United States)	Patent Expired Term	TREATMENT PROCESS FOR PROMOTING WEIGHT LOSS EMPLOYING A SUBSTITUTED $\Delta 5$ -ANDROSTENE	<b>Serial No.</b> 07/867,288 <b>Patent No.</b> 5,296,481
028USPT03 (United States)	Patent Expired Term	MODULATION OF IMMUNE SYSTEM WITH $\Delta 5$ - ANDROSTENES	<b>Serial No.</b> 07/922,850 <b>Patent No.</b> 5,292,730

*Schedule A to Assignment of Patents*

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
028USPT06 (United States)	Patent Expired Term	TREATMENT OF IMMUNE SYSTEM WITH $\Delta$ 5- ANDROSTENES	<b>Serial No.</b> 08/189,917 <b>Patent No.</b> 5,585,371
028USPT09 (United States)	Patent Expired MF	UP-REGULATION OF IMMUNE SYSTEM WITH $\Delta$ 5- ANDROSTENES	<b>Serial No.</b> 08/527,746 <b>Patent No.</b> 5,641,766
028USPT13 (United States)	Patent Expired MF	TREATMENT OF ALZHEIMER'S DISEASE AND MODULATION OF IMMUNE SYSTEM WITH $\Delta$ 5- ANDROSTENES	<b>Serial No.</b> 08/806,541 <b>Patent No.</b> 5,707,983
074CAPT01 (Canada)	Application Abandoned	USE OF $\Delta$ 5- ANDROSTENES IN THE TREATMENT OF HIV WASTING SYNDROME	<b>Serial No.</b> 2,276,783 <b>Patent No.</b>
074EPPT01 (Europe) Published in HK to preserve ability to extend EP Patent into HK.	Application Abandoned	USE OF $\Delta$ 5- ANDROSTENES IN THE TREATMENT OF HIV WASTING SYNDROME	<b>Serial No.</b> 98902561.4-2123 <b>Patent No.</b>
074USPT01 (United States)	Patent Expired MF	USE OF $\Delta$ 5- ANDROSTENES IN THE TREATMENT OF HIV WASTING SYNDROME	<b>Serial No.</b> 08/784,856 <b>Patent No.</b> 5,885,977
074WOPT01 (PCT)	Completed	USE OF $\Delta$ 5- ANDROSTENES IN THE TREATMENT OF HIV WASTING SYNDROME	<b>Serial No.</b> PCT/US98/00766 <b>Patent No.</b>
075USPT01 (United States)	Patent Expired	PROCESS FOR EFFECTING ALLYLIC OXIDATION	<b>Serial No.</b> 08/851,939

Schedule A to Assignment of Patents

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
	MF		<b>Patent No.</b> 5,869,709
075USPT02 (United States)	Patent Expired MF	PROCESS FOR EFFECTING ALLYLIC OXIDATION	<b>Serial No.</b> 09/228902 <b>Patent No.</b> 6,111,118
075USPT03 (United States)	Patent Expired MF	PROCESS FOR EFFECTING ALLYLIC OXIDATION	<b>Serial No.</b> 09/639,027 <b>Patent No.</b> 6,686,486
075WOPT01 (PCT)	Completed	PROCESS FOR EFFECTING ALLYLIC OXIDATION	<b>Serial No.</b> PCT/US98/09159 <b>Patent No.</b>
078USPT01 (United States)	Patent Expired MF	COPPER-CATALYSED ALLYLIC OXIDATION USING ALKYL HYDROPEROXIDE	<b>Serial No.</b> 08/901,764 <b>Patent No.</b> 6,252,119
090USPT01 (United States)	Patent Expired MF	PROCESS FOR EFFECTING ALLYLIC OXIDATION USING DICARBOXYLIC ACID IMIDES AND CHROMIUM REAGENTS	<b>Serial No.</b> 60/078,978 <b>Patent No.</b>
090USPT02 (United States)	Patent Expired MF	PROCESS FOR EFFECTING ALLYLIC OXIDATION USING DICARBOXYLIC ACID IMIDES AND CHROMIUM REAGENTS	<b>Serial No.</b> 09/423,467 <b>Patent No.</b> 6,384,251

*Schedule A to Assignment of Patents*

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
090WOPT02 (PCT)	Completed	PROCESS FOR EFFECTING ALLYLIC OXIDATION USING DICARBOXYLIC ACID IMIDES AND CHROMIUM REAGENTS	<b>Serial No.</b> PCT/US99/05609 <b>Patent No.</b>
092AUP02 (Australia)	Patent Expired MF	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 199913017 <b>Patent No.</b> 738,136
092AUP03 (Australia)	Patent Expired MF	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 200197049 <b>Patent No.</b> 777,497
092CAP02 (Canada)	Application Abandoned	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 2,310,632 <b>Patent No.</b>
092EPPT02 (Europe)	Application Abandoned	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 98956509.8 <b>Patent No.</b>
092USPT01 (United States)	Patent Expired MF	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 60/066,198 <b>Patent No.</b>
092USPT02 (United States)	Patent Expired MF	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 09/554,952 <b>Patent No.</b> 6,372,732
092USPT03 (United States)	Patent Expired MF	USE OF $\Delta^5$ -ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 10/106,580 <b>Patent No.</b> 6,593,316

Schedule A to Assignment of Patents

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
092USPT04 (United States)	Patent Expired MF	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> 10/431,960 <b>Patent No.</b> 6,924,274
092WOPT02 (PCT)	Completed	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS	<b>Serial No.</b> PCT/US98/23386 <b>Patent No.</b>
093AUPT02 (Australia)	Patent Expired MF	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF ARTHRITIS	<b>Serial No.</b> 199914142/99 <b>Patent No.</b> 766,908
093CAPT02 (Canada)	Application Abandoned	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF ARTHRITIS	<b>Serial No.</b> 2,311,471 <b>Patent No.</b>
093EPPT02 (Europe)	Application Abandoned	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF ARTHRITIS	<b>Serial No.</b> 98958020.4 <b>Patent No.</b>
093USPT01 (United States)	Application Abandoned	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF ARTHRITIS	<b>Serial No.</b> 60/066,197 <b>Patent No.</b>
093USPT02 (United States)	Patent Expired MF	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF ARTHRITIS	<b>Serial No.</b> 09/554,951 <b>Patent No.</b> 6,794,374
093WOPT02 (PCT)	Completed	USE OF $\Delta$ 5-ADROSTENE-3 $\beta$ - ol-7,17-DIONE IN THE TREATMENT OF ARTHRITIS	<b>Serial No.</b> PCT/US98/24458 <b>Patent No.</b>

Schedule A to Assignment of Patents

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
111CAPT01 (Canada)	Application Abandoned	IMPROVING MEMORY BY THE ADMINISTRATION OF $\Delta^5$ - ADROSTENE-3 $\beta$ -ol-7,17- DIONE AND 3 $\beta$ ESTERS THEREOF	<b>Serial No.</b> 2,344,677 <b>Patent No.</b>
111EPPT01 (Europe) Validated in DE and GB	Patent Expired MF	IMPROVING MEMORY BY THE ADMINISTRATION OF $\Delta^5$ - ADROSTENE-3 $\beta$ -ol-7,17- DIONE AND 3 $\beta$ ESTERS THEREOF	<b>Serial No.</b> 99954931.4 <b>Patent No.</b> 1,123,100
111JPPT01 (Japan)	Application Abandoned	IMPROVING MEMORY BY THE ADMINISTRATION OF $\Delta^5$ - ADROSTENE-3 $\beta$ -ol-7,17- DIONE AND 3 $\beta$ ESTERS THEREOF	<b>Serial No.</b> 2000-576854 <b>Patent No.</b>
111USPT01 (United States)	Issued Expires 18/10/16 Term	MEMORY ENHANCEMENT BY THE ADMINISTRATION OF $\Delta^5$ - ADROSTENE-3 $\beta$ -ol-7,17- DIONE AND 3 $\beta$ ESTERS THEREOF	<b>Serial No.</b> 09/174,235 <b>Patent No.</b> 6,153,606
111USPT02 (United States)	Issued Expires 18/10/16 Term	MEMORY BY THE ADMINISTRATION OF $\Delta^5$ - ADROSTENE-3 $\beta$ -ol-7,17- DIONE AND 3 $\beta$ ESTERS THEREOF	<b>Serial No.</b> 09/704,495 <b>Patent No.</b> 6,489,313
111WOPT01 (PCT)	Completed	MEMORY ENHANCEMENT BY THE ADMINISTRATION OF $\Delta^5$ - ADROSTENE-3 $\beta$ -ol-7,17- DIONE AND 3 $\beta$ ESTERS THEREOF	<b>Serial No.</b> PCT/US99/24076 <b>Patent No.</b>
161USPT01 (United States)	Application Abandoned	INCREASING BIOLOGICAL WELLNESS RATIO	<b>Serial No.</b> 60/142,709 <b>Patent No.</b>
161USPT02 (United States)	Application Abandoned	INCREASING BIOLOGICAL WELLNESS RATIO	<b>Serial No.</b> 09/611,762 <b>Patent No.</b>

Schedule A to Assignment of Patents

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
188USPT01 (United States)	Application Abandoned	TREATMENT OF CROHN'S DISEASE BY THE ADMINISTRATION OF DELTA5-ANDROSTENE-3- ACETOXY-7,17-DIONE	<b>Serial No.</b> 09/665,640 <b>Patent No.</b>
188WOPT01 (PCT)	Abandoned	TREATMENT OF CROHN'S DISEASE BY THE ADMINISTRATION OF DELTA5-ANDROSTENE-3- ACETOXY-7,17-DIONE	<b>Serial No.</b> PCT/US01/28895 <b>Patent No.</b>
205USPT01 (United States)	Application Abandoned	TREATMENT OF CHRONIC FATIGUE SYNDROME AND FIBROMYALGIA SYNDROME	<b>Serial No.</b> 60/250,227 <b>Patent No.</b>
205USPT02 (United States)	Issued Expires 25/01/04 Term	TREATMENT OF CHRONIC FATIGUE SYNDROME AND FIBROMYALGIA SYNDROME	<b>Serial No.</b> 10/433,043 <b>Patent No.</b> <b>7,553,829</b>
205WOPT02 (PCT)	Completed	TREATMENT OF CHRONIC FATIGUE SYNDROME AND FIBROMYALGIA SYNDROME	<b>Serial No.</b> PCT/US01/46241 <b>Patent No.</b>
208USPT01 (United States)	Patent Expired MF	METHOD OF MOISTURIZING THE SKIN BY THE TOPICAL APPLICATION OF DELTA5- ANDROSTENE-3BETA-OL- 7,17 DIONE AND METABOLIZABLE PRECURSORS THEREOF	<b>Serial No.</b> 09/799,313 <b>Patent No.</b> 6,399,085
209USPT01 (United States)	Patent Expired MF	METHOD FOR DIMINISHING WRINKLES AND FINE LINES OF THE SKIN BY THE TOPICAL APPLICATION OF DELTA5- ANDROSTENE-3BETA-OL- 7,17 DIONE AND METABOLIZABLE	<b>Serial No.</b> 09/799,295 <b>Patent No.</b> 6,399,084

Schedule A to Assignment of Patents



<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
210USPT01 (United States)	Patent Expired MF	TREATMENT OF DERMITITIS BY THE TOPICAL APPLICATION OF DELTA5- ANDROSTENE-3BETA-OL- 7,17 DIONE AND METABOLIZABLE PRECURSORS THEREOF	<b>Serial No.</b> 09/805,024 <b>Patent No.</b> 6,465,446
248USPT01 (United States)	Application Abandoned	METHOD OF PROMOTING WEIGHT LOSS AND FAT LOSS BY ADMINISTRATION OF 7- OXO DHEA AT A LOW DOSE RATE (50 mg/day)	<b>Serial No.</b> 60/604626 <b>Patent No.</b>
249USPT01 (United States)	Application Abandoned	METHOD OF PROMOTING WEIGHT LOSS AND FAT LOSS BY ADMINISTRATION OF 7- OXO DHEA AT A LOW DOSE RATE (100 mg/day)	<b>Serial No.</b> 60/604625 <b>Patent No.</b>
250USPT01 (United States)	Application Abandoned	METHOD OF PROMOTING WEIGHT LOSS AND FAT LOSS BY ADMINISTRATION OF 7- OXO DHEA AT A LOW DOSE RATE (150 mg/day)	<b>Serial No.</b> 60/604527 <b>Patent No.</b>
251USPT01 (United States)	Application Abandoned	METHOD OF ACHIEVING ACCELERATED WEIGHT LOSS BY ADMINISTRATION OF A WEIGHT LOSS ACCELERATING AGENT TO A DIETING MAMMAL [7-OXO DHEA]	<b>Serial No.</b> 60/439,753 <b>Patent No.</b>
251USPT02 (United States)	Application Abandoned	METHOD OF ACHIEVING ACCELERATED WEIGHT LOSS BY ADMINISTRATION OF A WEIGHT LOSS ACCELERATING AGENT TO A DIETING MAMMAL [7-OXO DHEA]	<b>Serial No.</b> 10/541781 <b>Patent No.</b>

Schedule A to Assignment of Patents

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
251WOPT02 (PCT)	Completed	METHOD OF ACHIEVING ACCELERATED WEIGHT LOSS BY ADMINISTRATION OF A WEIGHT LOSS ACCELERATING AGENT TO A DIETING MAMMAL [7-OXO DHEA]	<b>Serial No.</b> US2004/000537 <b>Patent No.</b>
253AUP01 (Australia)	Patent Expired MF	METHOD OF MODULATING THE BASAL METABOLIC RATE OF A DIETING MAMMAL BY ADMINISTRATION OF A METABOLIC MODULATING AGENT TO THE DIETING MAMMAL	<b>Serial No.</b> 2004200067 <b>Patent No.</b> 2004200067
253CAP01 (Canada)	Application Abandoned	METHOD OF MODULATING THE BASAL METABOLIC RATE OF A DIETING MAMMAL BY ADMINISTRATION OF A METABOLIC MODULATING AGENT TO THE DIETING MAMMAL [7-OXO DHEA]	<b>Serial No.</b> 2,453,282 <b>Patent No.</b>
253EPPT01 (Europe)	Application Abandoned	METHOD OF MODULATING THE BASAL METABOLIC RATE OF A DIETING MAMMAL BY ADMINISTRATION OF A METABOLIC MODULATING AGENT TO THE DIETING MAMMAL [7-OXO DHEA]	<b>Serial No.</b> 04000543.1 <b>Patent No.</b>
253JPPT01 (Japan)	Application Abandoned	METHOD OF MODULATING THE BASAL METABOLIC RATE OF A DIETING MAMMAL BY ADMINISTRATION OF A METABOLIC MODULATING AGENT TO THE DIETING MAMMAL [7-OXO DHEA]	<b>Serial No.</b> 2004-4160 <b>Patent No.</b>

Schedule A to Assignment of Patents

<b>SLO FILE # (COUNTRY)</b>	<b>STATUS EXPIRATION DATE (yy/mm/dd)</b>	<b>TITLE</b>	<b>SERIAL NO. PATENT NO.</b>
253NZPT01 (New Zealand)	Application Abandoned	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal [7-oxo DHEA]	<b>Serial No.</b> 530282 <b>Patent No.</b>
253USPT01 (United States)	Issued Expires 24/09/26 Term	METHOD OF MODULATING THE BASAL METABOLIC RATE OF A DIETING MAMMAL BY ADMINISTRATION OF A METABOLIC MODULATING AGENT TO THE DIETING MAMMAL	<b>Serial No.</b> 10/340,980 <b>Patent No.</b> 7,199,116
254USPT01 (United States)	Application Abandoned	METHOD OF ACHIEVING ACCELERATED FAT LOSS BY ADMINISTRATION OF A FAT LOSS ACCELERATING AGENT TO A DIETING MAMMAL	<b>Serial No.</b> 60/439,816 <b>Patent No.</b>
254USPT02 (United States)	Application Abandoned	METHOD OF ACHIEVING ACCELERATED FAT LOSS BY ADMINISTRATION OF A FAT LOSS ACCELERATING AGENT TO A DIETING MAMMAL	<b>Serial No.</b> 10/541780 <b>Patent No.</b>
254WOPT02 (PCT)	Completed	METHOD OF ACHIEVING ACCELERATED FAT LOSS BY ADMINISTRATION OF A FAT LOSS ACCELERATING AGENT TO A DIETING MAMMAL	<b>Serial No.</b> US2004/000541 <b>Patent No.</b>

Schedule A to Assignment of Patents

SLO FILE # (COUNTRY)	STATUS EXPIRATION DATE (yy/mm/dd)	TITLE	SERIAL NO. PATENT NO.
258USPT01 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND GREEN TEA EXTRACT AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC	<b>Serial No.</b> 60/488,433 <b>Patent No.</b>
258USPT02 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND GREEN TEA EXTRACT AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC	<b>Serial No.</b> 10/892,060 <b>Patent No.</b>
262USPT01 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND CONJUGATED LINOLEIC ACID AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOSITION	<b>Serial No.</b> 60/488,695 <b>Patent No.</b>
262USPT02 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND CONJUGATED LINOLEIC ACID AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOSITION	<b>Serial No.</b> 10/893,445 <b>Patent No.</b>

Schedule A to Assignment of Patents

SLO FILE # (COUNTRY)	STATUS EXPIRATION DATE (yy/mm/dd)	TITLE	SERIAL NO. PATENT NO.
263USPT01 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND PHASEOLUS VULGARIS AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOSITION	<b>Serial No.</b> 60/488,412 <b>Patent No.</b>
263USPT02 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND PHASEOLUS VULGARIS AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOSITION	<b>Serial No.</b> 10/892,059 <b>Patent No.</b>
264USPT01 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND A SOURCE OF BIOAVAILABLE CHROMIUM AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOSITION	<b>Serial No.</b> 60/488,429 <b>Patent No.</b>
289USPT01 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA AND A SOURCE OF BIOAVAILABLE CALCIUM AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOUND	<b>Serial No.</b> 60/604,721 <b>Patent No.</b>

Schedule A to Assignment of Patents

SLO FILE # (COUNTRY)	STATUS EXPIRATION DATE <i>(yy/mm/dd)</i>	TITLE	SERIAL NO. PATENT NO.
290AAPT02 (Australia)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA, A SOURCE OF BIOAVAILABLE CHROMIUM, A SOURCE OF BIOAVAILABLE CALCIUM, GREEN TEA EXTRACT, AND VITAMINS C AND D, AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOUND	<b>Serial No.</b> 2005271536 <b>Patent No.</b>

SLO FILE # (COUNTRY)	STATUS EXPIRATION DATE (yy/mm/dd)	TITLE	SERIAL NO. PATENT NO.
290USPT01 (United States)	Application Abandoned	COMPOSITION CONTAINING 7-OXO DHEA, A SOURCE OF BIOAVAILABLE CHROMIUM, A SOURCE OF BIOAVAILABLE CALCIUM, GREEN TEA EXTRACT, AND VITAMINS C AND D, AND METHOD OF PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF A DIETING INDUCED CHANGE IN BASAL METABOLIC RATE BY ADMINISTRATION OF THE COMPOUND	<b>Serial No.</b> 60/599,469 <b>Patent No.</b>
290USPT02 (United States)	Application Abandoned	COMPOSITION AND METHOD FOR PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF METABOLIC RATE	<b>Serial No.</b> 11/570,903 <b>Patent No.</b>
290WOPT02 (PCT)	Completed	COMPOSITION AND METHOD FOR PROMOTING WEIGHT LOSS, FAT LOSS OR MODULATION OF METABOLIC RATE	<b>Serial No.</b> PCT/US2005/0275 18 <b>Patent No.</b>

Schedule A to Assignment of Patents

WEIL:44498097:10:54281.0005

RECORDED: 08/27/2014

PATENT  
REEL: 033645 FRAME: 0234